New in town: Hae! Mee — 25-year-old Bai Nian 2nd-gen sells prawn noodles with palm-sized prawns
25-year-old owner Chantal Pang, a single mother of 2, didn't exactly have a good relationship with her family. She got pregnant at 19. Despite her parents' advice and disapproval, she still ran away from home with her ex-husband. As a result, her family decided to cut ties.
Life outside was tough for Chantal as she juggled multiple jobs while taking care of her newborn. As she grew older, she realised that her parents just wanted the best for her and didn't want her to live a life of regret.
Thus, Chantal sincerely wanted to reconcile with her family and regain their trust. Her brother asked if she wanted to work at the claypot shop. Since she had amassed some experience during her younger days when helping out at her parent's stall, she agreed.
Over time, she reconciled with them and her kids got to connect with their grandparents. She later decided to build her own F&B brand that symbolises home and growth, and that's when Hae! Mee came to fruition.
To ensure Chantal receives only the freshest palm-sized prawns daily, her brother Tommy, who had working relationships with seafood suppliers at Jurong Fishery Port seafood, connected her with them.
There are 4 options of noodles available — kway teow, yellow mee, and bee hoon — each served either dry or soup. The Signature Big Prawn Noodle (S$11.90), the chef's choice, contains 2 massive prawns, prawn paste, pork slices and pork lard.
If you don't particularly fancy large prawns, you can go for the normal sized ones like the Prawn Noodle (S$6.90) and Classic Prawn Noodle (S$8.90), which come with 4 prawns each. The only difference between the two is that the latter has 2 additional fried beancurd rolls.
You can also take your bowl of noodles to the next level by adding ingredients like Liver (S$1), Pig Skin (S$1) and Prawn Paste (S$2).
The menu also has delightful side dishes such as Golden Prawn Pancake (S$5.90), Golden Prawn Roll (S$5.90), and Hae Signature Fried Prawn (S$6.90 for 6 pieces). These are perfect for passing around to share among your family and friends!
Seeking a new prawn noodle spot to makan? Then head to Hae! Mee and see if they meet your standards.
Hong Lim Prawn Noodle: Highly-raved spot serving up gao, umami-packed prawn noodles
The post New in town: Hae! Mee — 25-year-old Bai Nian 2nd-gen sells prawn noodles with palm-sized prawns appeared first on SETHLUI.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
07-08-2025
- Yahoo
Analysts Estimate Haemonetics (HAE) to Report a Decline in Earnings: What to Look Out for
Haemonetics (HAE) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 7. On the other hand, if they miss, the stock may move lower. While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise. Zacks Consensus Estimate This provider blood management systems for health care providers and blood collectors is expected to post quarterly earnings of $1.01 per share in its upcoming report, which represents a year-over-year change of -1%. Revenues are expected to be $303.28 million, down 9.8% from the year-ago quarter. Estimate Revisions Trend The consensus EPS estimate for the quarter has been revised 0.22% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. Price, Consensus and EPS Surprise Earnings Whisper Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). How Have the Numbers Shaped Up for Haemonetics? For Haemonetics, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +1.24%. On the other hand, the stock currently carries a Zacks Rank of #4. So, this combination makes it difficult to conclusively predict that Haemonetics will beat the consensus EPS estimate. Does Earnings Surprise History Hold Any Clue? While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that Haemonetics would post earnings of $1.22 per share when it actually produced earnings of $1.24, delivering a surprise of +1.64%. Over the last four quarters, the company has beaten consensus EPS estimates two times. Bottom Line An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Haemonetics doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. An Industry Player's Expected Results Evolus, Inc. (EOLS), another stock in the Zacks Medical - Products industry, is expected to report loss per share of $0.09 for the quarter ended June 2025. This estimate points to a year-over-year change of -28.6%. Revenues for the quarter are expected to be $82.93 million, up 23.9% from the year-ago quarter. The consensus EPS estimate for Evolus has remained unchanged over the last 30 days. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -28.57%. This Earnings ESP, combined with its Zacks Rank #3 (Hold), makes it difficult to conclusively predict that Evolus will beat the consensus EPS estimate. The company could not beat consensus EPS estimates in any of the last four quarters. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report Evolus, Inc. (EOLS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-08-2025
- Yahoo
Haemonetics (HAE) Q1 Earnings and Revenues Surpass Estimates
Haemonetics (HAE) came out with quarterly earnings of $1.1 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $1.02 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +8.91%. A quarter ago, it was expected that this provider blood management systems for health care providers and blood collectors would post earnings of $1.22 per share when it actually produced earnings of $1.24, delivering a surprise of +1.64%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Haemonetics, which belongs to the Zacks Medical - Products industry, posted revenues of $321.39 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.97%. This compares to year-ago revenues of $336.17 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Haemonetics shares have lost about 3% since the beginning of the year versus the S&P 500's gain of 7.9%. What's Next for Haemonetics? While Haemonetics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Haemonetics was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.16 on $321.11 million in revenues for the coming quarter and $4.89 on $1.3 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Phibro Animal Health (PAHC), another stock in the same industry, has yet to report results for the quarter ended June 2025. This maker of animal health products and nutritional supplements is expected to post quarterly earnings of $0.52 per share in its upcoming report, which represents a year-over-year change of +26.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Phibro Animal Health's revenues are expected to be $361.15 million, up 32.2% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-08-2025
- Yahoo
Haemonetics 1st Quarter Fiscal Year 2026 Earnings Release Available on Investor Relations Website
Financial release accessible online BOSTON, Aug. 7, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal year 2026, which ended June 28, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 7, 2025. The conference call and webcast can be accessed with the following information: Teleconference link: Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start. A live webcast of the call can be accessed on Haemonetics' investor relations website or via the following link: In addition, the Company has posted to its Investor Relations website the earnings release that will be referenced on its conference call and webcast, a link to which is available below. Direct link to 1Q FY26 Earnings Release: A replay of the conference call and webcast will be available for one year beginning on August 7, 2025, at 11:00 a.m. ET using the conference call webcast link provided in this press release. ABOUT HAEMONETICSHaemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit Investor Contacts: Olga Guyette, Vice President-Investor Relations & Treasury David Trenk, Manager-Investor Relations (781) 356-9763 (203) 733-4987 Media Contact: Josh Gitelson, Sr. Director-Global Communications (781) 356-9776 original content to download multimedia: SOURCE Haemonetics Corporation
